2 news items
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
ITCI
18 Jun 24
.Falls. CAPLYTA may cause sleepiness or dizziness and can slow thinking and motor skills, which may lead to falls
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
ITCI
7 May 24
skills, which may lead to falls and, consequently, fractures and other injuries. Patients should be assessed for risk when using CAPLYTA
- Prev
- 1
- Next